Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Gynuity Health Projects Family Care International |
---|---|
Information provided by: | Gynuity Health Projects |
ClinicalTrials.gov Identifier: | NCT00116350 |
The purpose of this study is to test whether misoprostol is as effective as oxytocin for treating primary postpartum hemorrhage (PPH) with uterine atony as the suspected cause in two circumstances: 1) where women have received prophylactic uterotonics in the third stage of labor; and 2) where no prophylactic uterotonics have been given in the third stage of labor.
Condition | Intervention |
---|---|
Postpartum Hemorrhage |
Drug: Misoprostol |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Misoprostol for the Treatment of Primary Postpartum Hemorrhage |
Estimated Enrollment: | 1900 |
Study Start Date: | July 2005 |
Postpartum hemorrhage (PPH) remains a major cause of maternal deaths worldwide. Misoprostol offers several advantages over oxytocin and ergometrine, the drugs currently used to treat PPH. For example, misoprostol is stable at high temperatures and has a shelf life of several years, it is easy to administer, it can be given to hypertensive patients, and it is inexpensive. This randomized, double-blind placebo-controlled trial will test whether misoprostol is as effective as oxytocin in treating primary PPH in hospital births, both when women have received prophylactic uterotonics in the third stage of labor and when they have not.
Blood loss will be measured for all consenting women who deliver vaginally. If PPH occurs and uterine atony is the suspected cause, women will be randomized to receive either: a) four 200 µg pills of misoprostol sublingually and an IV of saline (resembling oxytocin) or b) four placebo tablets resembling misoprostol sublingually and 40 IU oxytocin by IV. This study seeks to answer the following questions:
This study will take place in hospitals located in Burkina Faso, Ecuador, Egypt, Turkey, and Vietnam.
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Burkina Faso | |
Centre Hospitalier Universitaire Souro Sanou de Bobo Dioulasso | |
Bobo Diolasso, Burkina Faso | |
Ecuador | |
Isidro Ayora Maternity Hospital | |
Quito, Ecuador | |
Egypt | |
Alexandria University Hospital, Shatby Maternity Hospital | |
Alexandria, Egypt | |
El-Galaa Teaching Hospital | |
Cairo, Egypt | |
Turkey | |
Ministry of Health Ankara Etlik Maternity and Teaching-Research Hospital | |
Ankara, Turkey, 06010 | |
Vietnam | |
Cu Chi Hospital, Tu Du Hospital, Hocmon Hospital, Binh Duong Hospital | |
Ho Chi Minh City and Binh Duong Province, Vietnam |
Principal Investigator: | Beverly Winikoff, MD, MPH | Gynuity Health Projects |
Study Director: | Jennifer Blum, MPH | Gynuity Health Projects |
Study Director: | Rasha Dabash, MPH | Gynuity Health Projects |
Study Director: | Sheila Raghavan, M.Sc. | Gynuity Health Projects |
Study Director: | Ayisha Diop, MPH | Gynuity Health Projects |
Study Director: | Ilana Dzuba, M.H.Sc. | Gynuity Health Projects |
Study ID Numbers: | 2.4.1, WIRB #20041878/1063615 |
Study First Received: | June 28, 2005 |
Last Updated: | April 24, 2008 |
ClinicalTrials.gov Identifier: | NCT00116350 |
Health Authority: | United States: Institutional Review Board |
Postpartum hemorrhage Misoprostol Developing countries Maternal morbidity Randomized controlled trial |
Postpartum Hemorrhage Pregnancy Complications Uterine Hemorrhage Puerperal Disorders |
Misoprostol Obstetric Labor Complications Hemorrhage |
Pathologic Processes Oxytocics Therapeutic Uses Anti-Ulcer Agents Physiological Effects of Drugs |
Abortifacient Agents Gastrointestinal Agents Reproductive Control Agents Abortifacient Agents, Nonsteroidal Pharmacologic Actions |